Increased Plasma Levels of Atrial Natriuretic Factor, Renin Activity, and Leukotriene C4 in Chronic Obstructive Pulmonary Disease

Piperno, D.; Pachéco, Yves; Hosni, R.; Molière, Patrick; Gharib, Claude; Lagarde, Michel; Perrin‐Fayolle, M

doi:10.1378/chest.104.2.454

Cited by 16 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 It is well established that the concentrations of cysteinyl leukotrienes are increased in the sputum, plasma and circulating leukocytes of patients with COPD implying that they could play a role in the pathophysiology of this disorder. [7][8][9][10][11][12][13] However, unlike certain patients with asthma, the effects of long-term therapy with cysteinyl leukotriene receptor antagonits on COPD control are uncertain. [14][15][16][17][18][19] Hence, the purpose of this retrospective study was to begin to address this issue by determining the effects of long-term treatment with montelukast, a cysteinyl leukotriene receptor antagonist, 6,18,20 on COPD control in a cohort of elderly patients with moderate to severe COPD residing in inner-city Chicago.…”

Section: Article In Pressmentioning

confidence: 99%

“…The concentration of cysteinyl leukotrienes is increased in the sputum, plasma and circulating leukocytes of patients with COPD. [7][8][9][10][11][12][13] To this end, Shindo et al 13 showed that circulating LTE 4 concentration increases significantly during acute exacerbations of COPD. Conceivably, elaboration of cysteinyl leukotrienes could play a role in the pathophysiology of airway inflammation in these patients.…”

Section: Article In Pressmentioning

confidence: 99%

See 1 more Smart Citation

Long-term montelukast therapy in moderate to severe COPD—a preliminary observation

Rubinstein

Kumar

Schriever

2004

Respiratory Medicine

View full text Add to dashboard Cite

The purpose of this retrospective study was to determine the effects of long-term treatment with montelukast on chronic obstructive pulmonary disease (COPD) control in a cohort of patients with moderate to severe COPD. The medical records of 20 consecutive male patients (18 African-Americans) aged 71.2 +/- 10.7 years diagnosed with moderate to severe COPD at the VA Chicago Health Care System, Chicago, Illinois, USA, and treated with oral montelukast, 10 mg every night, for 23.6 +/- 7.3 months were reviewed. Information on demographics and COPD control was extracted from each record. In each patient, a comparable follow-up period in the clinic before and after initiating montelukast therapy was reviewed and tabulated so each patient served as his own control. There was a significant improvement in complaints of shortness of breath, sputum production wheezing and nocturnal symptoms during the observation period (P < 0.05). There was a significant reduction in the use of oral and inhaled corticosteroids, inhaled bronchodilators and supplemental oxygen (P < 0.05). In addition, there was a significant reduction in the number of visits to the emergency department, number of hospitalizations and duration of hospitalizations for acute exacerbations of COPD (P < 0.05). No significant changes in FEV1 (% predicted), FEV1/FVC ratio (% predicted) and peak expiratory flow rate were recorded during this time. No side effects where reported during the observation period and no patient discontinued the medication. Collectively, these data suggest that long-term treatment with montelukast is safe and improves COPD control in elderly patients with moderate to severe COPD.

show abstract

Section: Article In Pressmentioning

confidence: 99%

Section: Article In Pressmentioning

confidence: 99%

Long-term montelukast therapy in moderate to severe COPD—a preliminary observation

Rubinstein

Kumar

Schriever

2004

Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…In contrast, Piperno et al . demonstrated that LTC 4 but not LTB 4 is detectable in the plasma of patients with COPD [15]. However, plasma levels of leukotrienes are difficult to interpret due to release from inflammatory cells and metabolism.…”

Section: Introductionmentioning

confidence: 99%

Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease

Antczak

Ciebiada²,

Pietras³

et al. 2012

aoms

View full text Add to dashboard Cite

IntroductionEicosanoids and oxidants play an important role in inflammation, but their role in chronic obstructive pulmonary disease (COPD) is uncertain. In this study we hypothesized that levels of exhaled leukotrienes, prostaglandins and biomarkers of oxidative stress are increased in infectious exacerbations of COPD and that they decrease after antibiotic therapy.Material and methodsCysteinyl-leukotrienes (LTs), leukotriene B4 (LTB4), prostaglandin E4, hydrogen peroxide (H2O2) and 8-isoprostane were measured in exhaled breath condensate (EBC) in 16 COPD patients with infectious exacerbations (mean age 64 ±12 years, 13 male) on day 1, during antibiotic therapy (days 2-4), 2-4 days after therapy and at a follow-up visit when stable (21-28 days after therapy).ResultsThere was a significant fall in concentration of cys-LTs, LTB4 and 8-isoprostane at visit 3 compared to day 1 (cys-LTs: 196.5 ±38.4 pg/ml vs. 50.1 ±8.2 pg/ml, p < 0.002; LTB4: 153.6 ±25.5 pg/ml vs. 71.9 ±11.3 pg/ml, p < 0.05; 8-isoprostane: 121.4 ±14.6 pg/ml vs. 56.1 ±5.2 pg/ml, p < 0.03, respectively). Exhaled H2O2 was higher on day 1 compared to that at visits 2 and 3 (0.74 ±0.046 µM vs. 0.52 ±0.028 µM and 0.35 ±0.029 µM, p < 0.01 and p < 0.01, respectively). Exhaled PGE2 levels did not change during exacerbations of COPD. Exhaled eicosanoids and H2O2 in EBC measured at the follow-up visit (stable COPD) were significantly higher compared to those from healthy subjects.ConclusionsWe conclude that eicosanoids and oxidants are increased in infectious exacerbations of COPD. They are also elevated in the airways of stable COPD patients compared to healthy subjects.

show abstract

“…2 The role of CysLTs in chronic obstructive pulmonary disease (COPD) remains uncertain despite previous but limited evidence which indicates increased production in different fluids in this disorder. 3,4 However, there is evidence that CysLTs increase microvascular permeability, evoke mucus hypersecretion and are potent smooth muscle constriction agents, 5 features that are present in the airways of COPD patients, and this suggests that they might play a role in this disorder.…”

mentioning

confidence: 99%

Leukotriene E4 in urine in patients with asthma and COPD—The effect of smoking habit

Gaki

Papatheodorou

Ischaki

et al. 2007

Respiratory Medicine

View full text Add to dashboard Cite

Leukotriene E(4) (LTE(4)) is implicated in asthma pathophysiology and possibly in chronic obstructive pulmonary disease (COPD) as one of the causes of persistent bronchoconstriction and mucus hypersecretion. Cigarette smoking stimulates cysteinyl leukotrienes (CysLTs) production. We investigated whether LTE(4) is equally increased in asthma and COPD and whether smoking significantly affects LTE(4) levels. Secondary outcomes involved correlations with inflammatory and functional parameters. We studied 40 patients with COPD [20 smokers], 40 asthmatics [20 smokers] and 30 healthy subjects [15 smokers]. Spirometry (FEV(1)% pred., FEV(1)/FVC) was performed, urine was collected for measurement of LTE(4) and creatinine, induced sputum was collected for differential cell counts and serum for ECP. LTE(4)/creatinine levels (pg/mg) [mean (sd)] were increased in asthmatic patients compared to COPD and controls, [125.6(54.5) vs. 54.5(19) vs. 55.9(18.9)pg/mg, respectively, P<0.0001 for asthma]. Smoking significantly affects LTE(4) levels only in asthmatic patients [164 (48) vs. 87 (26.3), P<0.0001 for smokers]. The only significant correlation was between eosinophils in induced sputum and LTE(4)/creatinine levels in asthmatics. In conclusion, patients with asthma presented higher LTE(4) values compared to normals and patients with COPD. Smoking significantly affects LTE(4) values only in asthmatics indicating a different underlying CysLTs inflammatory process in this condition.

show abstract

Increased Plasma Levels of Atrial Natriuretic Factor, Renin Activity, and Leukotriene C4 in Chronic Obstructive Pulmonary Disease

Cited by 16 publications

References 35 publications

Long-term montelukast therapy in moderate to severe COPD—a preliminary observation

Long-term montelukast therapy in moderate to severe COPD—a preliminary observation

Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease

Leukotriene E4 in urine in patients with asthma and COPD—The effect of smoking habit

Contact Info

Product

Resources

About